<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Sarah Gilbert</title><meta name="description" content="Dame Sarah Catherine Gilbert DBE FRS FMedSci (born April 1962) is a British vaccinologist serving as the Saïd Professor of Vaccinology at the University of Oxford&#x27;s Jenner Institute. Her research centers on viral vectored vaccines designed to elicit robust T cell and B cell immune responses against infectious diseases, including influenza and emerging pathogens such as MERS coronavirus, Nipah virus, and Lassa virus. In January 2020, Gilbert became the Oxford Project Leader for ChAdOx1 nCoV-19,..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Sarah_Gilbert"/><meta property="og:title" content="Sarah Gilbert"/><meta property="og:description" content="Dame Sarah Catherine Gilbert DBE FRS FMedSci (born April 1962) is a British vaccinologist serving as the Saïd Professor of Vaccinology at the University of Oxford&#x27;s Jenner Institute. Her research centers on viral vectored vaccines designed to elicit robust T cell and B cell immune responses against infectious diseases, including influenza and emerging pathogens such as MERS coronavirus, Nipah virus, and Lassa virus. In January 2020, Gilbert became the Oxford Project Leader for ChAdOx1 nCoV-19,..."/><meta property="og:url" content="https://grokipedia.com/page/Sarah_Gilbert"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Sarah Gilbert"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:43.466Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Sarah Gilbert"/><meta name="twitter:description" content="Dame Sarah Catherine Gilbert DBE FRS FMedSci (born April 1962) is a British vaccinologist serving as the Saïd Professor of Vaccinology at the University of Oxford&#x27;s Jenner Institute. Her research centers on viral vectored vaccines designed to elicit robust T cell and B cell immune responses against infectious diseases, including influenza and emerging pathogens such as MERS coronavirus, Nipah virus, and Lassa virus. In January 2020, Gilbert became the Oxford Project Leader for ChAdOx1 nCoV-19,..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="ea3d07bb1a006d44485bc770229d68e1-82cf0837bcc9fe24-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=ea3d07bb1a006d44485bc770229d68e1,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.9454073425161893,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>⌘</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>⌘</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#sarah-gilbert" class="transition-opacity hover:opacity-100 opacity-50">Sarah Gilbert</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#biography" class="transition-opacity hover:opacity-100 opacity-50">Biography</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#early-life" class="transition-opacity hover:opacity-100 opacity-50">Early life</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#education" class="transition-opacity hover:opacity-100 opacity-50">Education</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#scientific-career" class="transition-opacity hover:opacity-100 opacity-50">Scientific Career</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pre-covid-research-on-viral-vaccines" class="transition-opacity hover:opacity-100 opacity-50">Pre-COVID research on viral vaccines</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#development-of-the-oxford-astrazeneca-covid-19-vaccine" class="transition-opacity hover:opacity-100 opacity-50">Development of the Oxford-AstraZeneca COVID-19 vaccine</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#post-vaccine-research-and-ongoing-contributions" class="transition-opacity hover:opacity-100 opacity-50">Post-vaccine research and ongoing contributions</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#vaccine-specific-analysis" class="transition-opacity hover:opacity-100 opacity-50">Vaccine-Specific Analysis</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-trials-and-efficacy-data" class="transition-opacity hover:opacity-100 opacity-50">Clinical trials and efficacy data</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#safety-profile-and-adverse-events" class="transition-opacity hover:opacity-100 opacity-50">Safety profile and adverse events</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#global-rollout-impact-and-withdrawal" class="transition-opacity hover:opacity-100 opacity-50">Global rollout, impact, and withdrawal</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#recognition-and-honors" class="transition-opacity hover:opacity-100 opacity-50">Recognition and Honors</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#major-awards-and-titles" class="transition-opacity hover:opacity-100 opacity-50">Major awards and titles</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#public-lectures-and-media-engagements" class="transition-opacity hover:opacity-100 opacity-50">Public lectures and media engagements</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#personal-life" class="transition-opacity hover:opacity-100 opacity-50">Personal Life</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#family-and-private-interests" class="transition-opacity hover:opacity-100 opacity-50">Family and private interests</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="sarah-gilbert" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Sarah Gilbert<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">
Dame Sarah Catherine Gilbert DBE FRS FMedSci (born April 1962) is a British vaccinologist serving as the Saïd Professor of Vaccinology at the University of Oxford&#x27;s Jenner Institute.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Her research centers on viral vectored vaccines designed to elicit robust T cell and B cell immune responses against infectious diseases, including influenza and emerging pathogens such as MERS coronavirus, Nipah virus, and Lassa virus.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In January 2020, Gilbert became the Oxford Project Leader for ChAdOx1 nCoV-19, an adenovirus-vectored vaccine candidate against SARS-CoV-2 that was developed using pre-existing chimpanzee adenovirus platforms to enable rapid adaptation to the novel coronavirus.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_21abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_31abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> This vaccine, partnered with AstraZeneca, underwent clinical trials demonstrating efficacy in preventing symptomatic COVID-19 and received emergency use authorization in over 170 countries, contributing to global vaccination efforts despite subsequent scrutiny over rare adverse events like vaccine-induced thrombotic thrombocytopenia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_61abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Gilbert&#x27;s prior work on universal influenza vaccines and candidates for Ebola and malaria underscored the platform&#x27;s versatility for pandemic preparedness.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_81abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_91abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For her contributions, Gilbert has been honored with the Dame Commander of the Order of the British Empire, Fellowship of the Royal Society, and the Royal Society&#x27;s Copley Medal awarded to the Oxford vaccine team, recognizing advancements in collaborative vaccine innovation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_21qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_31qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Her approach prioritizes empirical testing of vectored technologies to address viral threats through cellular immunity, distinct from traditional antibody-focused strategies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<h2 id="biography" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Biography<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="early-life" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Early life<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Sarah Catherine Gilbert was born in April 1962 in Kettering, Northamptonshire, England.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_23abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_33abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Her father worked as an office manager for a shoemaking company, and her mother was an English teacher; neither parent had a background in science, technology, engineering, or mathematics fields.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_23qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_33qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> Little is publicly documented about her childhood beyond these family circumstances, which were typical of mid-20th-century working-class households in the region.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_53qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<h3 id="education" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Education<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Sarah Gilbert attended Kettering High School for Girls, where she developed an interest in medicine.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_24qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup> She earned a Bachelor of Science degree in biological sciences, specializing in microbiology, from the University of East Anglia in 1983, graduating with first-class honors and receiving a prize for the highest academic achievement in her specialization.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_64qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Gilbert completed her PhD at the University of Hull, focusing on molecular biology aspects relevant to virology.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_25abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_35abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Following her doctorate, she pursued postdoctoral research, joining the University of Oxford in 1994 as a senior postdoctoral researcher in the Nuffield Department of Medicine.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_55abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_65abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<h2 id="scientific-career" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Scientific Career<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="pre-covid-research-on-viral-vaccines" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Pre-COVID research on viral vaccines<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Prior to the COVID-19 pandemic, Sarah Gilbert focused on viral-vectored vaccines employing the replication-deficient chimpanzee adenovirus ChAdOx1 platform, designed to induce potent cellular (T-cell) and humoral (antibody) immune responses against challenging viral targets. This approach, refined through her work at the Jenner Institute since 2005, emphasized conserved antigens to achieve broader protection, drawing from earlier experience in malaria vaccine vectors but applied specifically to viruses like influenza and emerging pathogens.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_26qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_36qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Gilbert led the Jenner Institute&#x27;s influenza vaccine program, targeting a universal influenza vaccine to overcome limitations of strain-matched seasonal shots by focusing on T-cell responses to internal viral proteins. In a 2012 review, she outlined progress in viral-vectored strategies for eliciting cross-reactive immunity against diverse influenza strains, including preclinical data on ChAdOx1-expressing nucleoprotein and matrix protein antigens.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_27abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> Her team advanced candidates into early clinical stages, with phase I trials demonstrating safety and immunogenicity in humans by inducing CD4+ and CD8+ T-cell responses durable beyond one year.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For Middle East Respiratory Syndrome coronavirus (MERS-CoV), Gilbert&#x27;s group developed the ChAdOx1 MERS vaccine, with preclinical studies from 2016 onward showing single-dose protection in mice and camels, including reduced lung viral loads by orders of magnitude and mitigation of pneumonia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_27qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_37qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup> The platform&#x27;s efficacy in animal models informed rapid adaptation for other coronaviruses, with phase I human trials initiated pre-2020 to assess safety in seronegative adults.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_57qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_67qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Gilbert extended the ChAdOx1 vector to henipaviruses, initiating Nipah virus vaccine research in 2017, which progressed to preclinical demonstrations of survival in African green monkeys following lethal challenge, via strong neutralizing antibodies and T-cell responses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_28abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_38abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> For Lassa fever, her team engineered ChAdOx1 Lassa-GPC, with 2019 platform reviews and subsequent guinea pig studies confirming full protection against lethal Josiah strain challenge through robust cellular and humoral immunity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_58abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_68abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> These efforts underscored Gilbert&#x27;s emphasis on platforms enabling swift responses to outbreak threats, with manufacturing pipelines established for first-in-human testing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_88abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h3 id="development-of-the-oxford-astrazeneca-covid-19-vaccine" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Development of the Oxford-AstraZeneca COVID-19 vaccine<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><br/>
The Oxford-AstraZeneca COVID-19 vaccine, designated ChAdOx1 nCoV-19, utilized a replication-deficient chimpanzee adenovirus vector platform (ChAdOx1) developed over two decades at the University of Oxford&#x27;s Jenner Institute. This platform originated in the early 2000s under Professor Adrian Hill, adapting a chimpanzee adenovirus serotype Y25 by deleting genes essential for replication and incorporating a human adenovirus gene to facilitate manufacturing. Prior applications included vaccines against malaria, influenza, and Ebola, with the vector demonstrating safety in thousands of human subjects across age groups.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_49abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_59abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Sarah Gilbert, Professor of Vaccinology at the Jenner Institute, served as the project leader for adapting the ChAdOx1 platform to target SARS-CoV-2. On January 10, 2020, following the public release of the viral genome, Gilbert and her team—including Professors Andrew Pollard, Teresa Lambe, Adrian Hill, and Dr. Sandy Douglas—began designing the vaccine construct by inserting the gene encoding the SARS-CoV-2 spike protein into the ChAdOx1 vector. This approach leveraged prior experience with a MERS coronavirus vaccine using the same vector, which had proven capable of eliciting strong T-cell and antibody responses. The design aimed for a single-dose regimen to rapidly induce immunity, capitalizing on the vector&#x27;s non-replicating nature and broad safety profile observed in previous trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_29qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_39qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_49qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Preclinical evaluation commenced promptly, with a laboratory version of the vaccine tested in mice by early February 2020, confirming robust immune responses against the spike protein. Funding from UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR), including a £2.6 million rapid response grant in March 2020, supported these investigations and preparation for human trials. The Jenner Institute&#x27;s Viral Vector Core Facility and Clinical Biomanufacturing Facility enabled rapid production of the candidate for testing. In parallel, Oxford partnered with AstraZeneca in March 2020 to accelerate large-scale manufacturing and global distribution, ensuring no-profit commitments for the pandemic phase. By April 2020, sufficient material was available for the first human dosing in phase I/II trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<h3 id="post-vaccine-research-and-ongoing-contributions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Post-vaccine research and ongoing contributions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Following the emergency authorization of the Oxford-AstraZeneca COVID-19 vaccine in late 2020, Sarah Gilbert has directed her efforts toward enhancing viral vectored vaccine platforms, with a focus on improving efficacy against emerging infectious diseases through stronger T cell and B cell responses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> At the Jenner Institute, University of Oxford, she has led advancements in chimpanzee adenovirus-vectored technologies, building on the ChAdOx1 vector used in the COVID-19 vaccine to target pathogens requiring robust cellular immunity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In September 2023, Gilbert&#x27;s team initiated a Phase I clinical trial for a MERS-CoV vaccine employing the ChAdOx1 platform, in partnership with the University of Liverpool&#x27;s Centre for Global Vaccine Research; the trial evaluates safety and immunogenicity in up to 50 healthy adults aged 18-55, aiming to address the high mortality rate of MERS outbreaks, which exceed 35% in confirmed cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup> This project extends her prior work on MERS vaccine candidates, prioritizing rapid-deployment vaccines for coronaviruses with pandemic potential.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Gilbert continues to oversee development of next-generation influenza vaccines, including efforts toward a universal flu vaccine capable of broader strain coverage beyond annual seasonal updates, amid ongoing refinements to antigen design and vector stability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup> Her portfolio also encompasses vaccines for other priority pathogens, such as Nipah virus, Lassa fever virus, and Crimean-Congo haemorrhagic fever virus, with preclinical and early-stage trials emphasizing cross-protective immunity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup> In January 2025, she was appointed Deputy Head of the Jenner Institute, where she now coordinates multi-pathogen vaccine pipelines and technology optimizations to accelerate responses to future outbreaks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">These initiatives reflect Gilbert&#x27;s emphasis on proactive platform-based vaccine design, enabling faster adaptation to novel threats compared to traditional inactivated or protein subunit approaches, as evidenced by her group&#x27;s track record in compressing development timelines from years to months during the COVID-19 response.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup></span>
<h2 id="vaccine-specific-analysis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Vaccine-Specific Analysis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="clinical-trials-and-efficacy-data" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Clinical trials and efficacy data<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The ChAdOx1 nCoV-19 (AZD1222) vaccine underwent phase 3 evaluation in randomized, placebo-controlled trials including COV002 (UK, n=11,734 analyzed for efficacy), COV003 (Brazil, n=4,228), and COV005 (South Africa, n=1,753 HIV-uninfected participants).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> An interim pooled analysis across these trials, published in December 2020, reported overall efficacy of 70.4% (95% CI 54.8–80.6) against symptomatic COVID-19 at least 14 days after the second dose, with zero cases of hospitalization or severe disease in the vaccine arm (versus two severe cases and one death in placebo).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A subsequent pooled analysis of the same trials, focusing on dosing regimens, found efficacy of 66.7% (95% CI 57.4–74.0) more than 14 days after two full doses, with 84 symptomatic cases among 8,597 vaccine recipients versus 254 among 8,073 placebo recipients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup> Efficacy after a single standard dose was 76.0% (95% CI 59.3–85.9) from day 22 to day 90 post-vaccination, based on 53 cases in 2,141 vaccine recipients versus 91 in 2,227 placebo recipients during that period.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup> Interval between doses influenced outcomes: two full doses yielded 55.1% efficacy (95% CI 33.0–69.9; 30 cases in 1,761 recipients) with less than 6 weeks spacing, rising to 81.3% (95% CI 60.3–91.2; 7 cases in 2,077 recipients) with more than 12 weeks spacing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Efficacy varied by SARS-CoV-2 variant. In the South African trial (February–April 2021 enrollment), where over 90% of sequenced cases were B.1.351 (beta variant), two doses showed 0% efficacy (95% CI –132.3 to 52.3; 23 cases in 717 vaccine recipients versus 28 in 750 placebo) against mild-to-moderate disease but 100% efficacy (95% CI –13.0 to 100) against severe or critical disease (zero events in vaccine arm versus two hospitalizations in placebo).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup> A separate phase 3 trial in the US (n=32,449), using a 4-week interval, reported 74.0% overall efficacy (95% CI 65.7–80.5) against symptomatic disease, with 76 hospitalizations in the vaccine group versus 185 in placebo.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup></span>
<h3 id="safety-profile-and-adverse-events" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Safety profile and adverse events<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In phase 3 clinical trials involving over 23,000 participants, the ChAdOx1 nCoV-19 vaccine demonstrated a favorable safety profile, with solicited adverse events primarily mild to moderate and resolving within a few days; these included injection-site pain (reported in 60-70% of recipients after the first dose), headache (50-60%), fatigue (50-60%), and myalgia (40-50%), occurring more frequently after the first dose than the second.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> Unsolicited adverse events were similar between vaccine and control groups, and no vaccine-related deaths or hospitalizations due to anaphylaxis were observed.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> Serious adverse events occurred at rates of 0.7 per 1000 in vaccine recipients versus 0.8 per 1000 in controls, with none deemed causally related to the vaccine.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Post-authorization surveillance identified rare but serious adverse events, notably thrombosis with thrombocytopenia syndrome (TTS), a condition involving venous or arterial thrombosis combined with low platelet counts and anti-platelet factor 4 antibodies, typically emerging 5-30 days after vaccination.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup> Incidence rates varied by age and sex, estimated at 2-3 cases per 100,000 doses overall, but up to 10-15 per 100,000 in women under 60 years in some European cohorts, with a case fatality rate of approximately 20-25%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup> This led to temporary suspensions and age-based restrictions in several countries, though regulatory reviews, including by the European Medicines Agency (EMA), confirmed no overall increase in thrombosis risk beyond TTS and affirmed that benefits exceeded risks given COVID-19&#x27;s higher thrombotic complications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_agqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Other rare events included Guillain-Barré syndrome (GBS), with EMA reporting 227 cases following about 51 million doses by mid-2021, prompting its addition to product labeling, though causality remains unconfirmed and rates were not elevated beyond background levels in some analyses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup> No significant signals for myocarditis or pericarditis emerged, unlike with mRNA vaccines.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup> Large-scale observational studies post-rollout corroborated trial findings, with serious adverse events remaining infrequent (under 1 per 10,000 doses) and self-resolving common side effects dominating reports.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup></span>
<h3 id="global-rollout-impact-and-withdrawal" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Global rollout, impact, and withdrawal<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The Oxford–AstraZeneca vaccine, marketed as Vaxzevria or Covishield in various regions, received emergency authorization in the United Kingdom on December 30, 2020, marking the start of its global rollout.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup> By March 2021, initial doses began arriving in low- and middle-income countries via the COVAX Facility, with AstraZeneca committing to supply hundreds of millions of doses at cost.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup> Over 2.5 billion doses were administered worldwide by early 2022, reaching more than 170 countries, particularly aiding equitable access in regions with limited mRNA vaccine availability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Real-world studies demonstrated substantial public health impact, with the vaccine estimated to have averted 6.3 million deaths in its first year of deployment (December 2020 to December 2021), outperforming other vaccines in global reach during that period due to its distribution to lower-income settings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup> Effectiveness against severe outcomes remained high, at 92% for hospitalization prevention after two doses in early variants, comparable to mRNA vaccines in preventing deaths and hospital admissions per expert reviews of observational data.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup> Broader modeling across 185 countries indicated vaccines like Oxford–AstraZeneca contributed to a 59% reduction in COVID-19 mortality in participating nations through March 2023, though efficacy waned against later variants without boosters.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Deployment faced interruptions in several countries starting March 2021 due to rare cases of thrombosis with thrombocytopenia syndrome (TTS), prompting pauses in Denmark (fully ceased April 2021), Norway, and others, with incidence rates of 1–2 per 100,000 doses primarily in younger adults.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> The United Kingdom discontinued routine use by winter 2021, favoring mRNA options for younger groups amid variant shifts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup> In May 2024, AstraZeneca initiated global withdrawal of Vaxzevria&#x27;s marketing authorizations, citing a surplus of updated vaccines targeting new variants and resulting low demand as the primary commercial rationale, rather than safety concerns.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup> The European Medicines Agency confirmed the EU authorization&#x27;s removal at the company&#x27;s request for these reasons, following earlier admissions in legal proceedings of a plausible causal link to TTS.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ajabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup></span>
<h2 id="recognition-and-honors" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Recognition and Honors<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="major-awards-and-titles" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Major awards and titles<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Gilbert was appointed <strong>Dame Commander of the Order of the British Empire (DBE)</strong> in the 2021 New Year Honours for services to scientific research and development in the response to the COVID-19 pandemic.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup> In March 2021, she received the <strong>Albert Medal</strong> from the Royal Society of Arts, Manufactures and Commerce, recognizing her leadership in developing the Oxford-AstraZeneca COVID-19 vaccine as a model of collaborative innovation for global health.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[58]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Later in 2021, Gilbert was awarded the <strong>Princess of Asturias Award for Technical &amp; Scientific Research</strong> (shared with other Oxford vaccine developers) for advancing viral vector vaccine platforms against multiple pathogens, including SARS-CoV-2.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup> She also received the <strong>Royal Society of Medicine Gold Medal</strong> that year for her contributions to medical research, particularly in vaccinology.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> In recognition of her vaccine work&#x27;s global impact, she was named a laureate of the <strong>Sunhak Peace Prize</strong> in 2022.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_clabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In 2023, Gilbert received the <strong>King Faisal International Prize for Medicine</strong> for pioneering viral vector vaccines applied to diseases such as malaria, Ebola, influenza, MERS, and COVID-19.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup> That October, she was granted the <strong>Freedom of the City of London</strong> for her role in developing an effective, scalable COVID-19 vaccine credited with saving over six million lives worldwide.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup> In March 2021, she was awarded the <strong>Barcroft Medal</strong> by Queen&#x27;s University Belfast for outstanding achievements in medical research.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_clqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">More recently, in April 2025, Gilbert was elected an <strong>Honorary Fellow</strong> of the Royal Society of Chemistry for co-developing the Oxford-AstraZeneca vaccine.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[62]</sup> In August 2025, she received the <strong>Woxsen Luminary Award for Outstanding Research Contributions</strong> from Woxsen University.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup></span>
<h3 id="public-lectures-and-media-engagements" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Public lectures and media engagements<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Professor Dame Sarah Gilbert has delivered several prominent public lectures on vaccine development and pandemic preparedness, often highlighting the role of viral vector technologies and the need for proactive global responses to emerging threats. These engagements underscore her advocacy for sustained investment in platform-based vaccine platforms, drawing from her experience with the ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In 2021, Gilbert presented the 44th Richard Dimbleby Lecture, titled &quot;Vaccine vs the Virus: This race, and the next one&quot;, broadcast by the BBC, in which she detailed the rapid adaptation of prior &quot;Disease X&quot; research to COVID-19, the logistical challenges overcome for emergency authorization by the UK&#x27;s MHRA on December 30, 2020, and the imperative for enhanced manufacturing capacity to address variants like Omicron.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[65]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">On June 25, 2025, she delivered the second 500th Anniversary Lecture for Christ Church, Oxford, at Oxford Town Hall, titled &quot;Preparation and pandemics: confronting new threats&quot;, chaired by BBC Health Editor Hugh Pym; the talk covered university-industry partnerships, work on viruses like Nipah, and key lessons from COVID-19 for mitigating future outbreaks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Gilbert gave the 2024 UCL Prize Lecture in Life and Medical Sciences on November 14, titled &quot;Vaccine development during and after the pandemic&quot;, where she described assembling multidisciplinary teams for ChAdOx1, its advantages for low-income countries due to non-frozen storage and its estimated millions of lives saved in the first year post-rollout, while stressing regulatory hurdles and the urgency of preparing for subsequent pandemics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">She has also spoken at the London School of Hygiene &amp; Tropical Medicine&#x27;s Vaccine Centre Annual Lecture on vaccines targeting outbreak pathogens, including Ebola in 2014 and the conceptual &quot;Disease X&quot; in 2020, followed by a public Q&amp;A to address ongoing post-pandemic requirements.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[68]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In media engagements, Gilbert has appeared in interviews and conferences, such as the Doherty Institute&#x27;s 2023 media event on COVID-19 vaccines and discussions with outlets like BBC Radio, emphasizing collaborative successes and communication challenges during crises.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[69]</sup></span>
<h2 id="personal-life" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Personal Life<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="family-and-private-interests" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Family and private interests<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Sarah Gilbert is married to Rob Blundell, a fellow scientist.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[71]</sup> The couple has three children, triplets consisting of daughters Susannah and Caitlin and son Freddie.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup> All three children pursued studies in biochemistry, with Susannah and Caitlin attending the University of Oxford and Freddie enrolling at the University of Manchester.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup> In late 2020, the triplets volunteered as participants in phase III clinical trials of the Oxford-AstraZeneca COVID-19 vaccine, reflecting a family-wide commitment to scientific advancement amid the pandemic.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_arabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_brabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[73]</sup> Gilbert and her family reside in Oxford.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_drabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[71]</sup> Little public information exists regarding her personal hobbies or non-professional pursuits, consistent with her emphasis on privacy outside of her scientific work.</span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="https://www.ndm.ox.ac.uk/team/sarah-gilbert" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ndm.ox.ac.uk/team/sarah-gilbert" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ndm.ox.ac.uk/team/sarah-gilbert</a></span></div></li><li id="https://royalsociety.org/people/sarah-gilbert-36200/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://royalsociety.org/people/sarah-gilbert-36200/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://royalsociety.org/people/sarah-gilbert-36200/</a></span></div></li><li id="https://www.tropicalmedicine.ox.ac.uk/team/sarah-gilbert" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tropicalmedicine.ox.ac.uk/team/sarah-gilbert" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.tropicalmedicine.ox.ac.uk/team/sarah-gilbert</a></span></div></li><li id="https://www.psi.ox.ac.uk/our-team/sarah-gilbert" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.psi.ox.ac.uk/our-team/sarah-gilbert" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.psi.ox.ac.uk/our-team/sarah-gilbert</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8704023/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8704023/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8704023/</a></span></div></li><li id="https://www.ox.ac.uk/news/2022-08-24-oxford-scientists-honoured-eight-royal-society-awards" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ox.ac.uk/news/2022-08-24-oxford-scientists-honoured-eight-royal-society-awards" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ox.ac.uk/news/2022-08-24-oxford-scientists-honoured-eight-royal-society-awards</a></span></div></li><li id="https://www.bbc.com/news/uk-55043551" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bbc.com/news/uk-55043551" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bbc.com/news/uk-55043551</a></span></div></li><li id="http://sunhakpeaceprize.org/en/laureates/laureates_view.php?idx=571" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://sunhakpeaceprize.org/en/laureates/laureates_view.php?idx=571" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">http://sunhakpeaceprize.org/en/laureates/laureates_view.php?idx=571</a></span></div></li><li id="https://www.hindustantimes.com/world-news/the-woman-behind-the-oxford-astrazeneca-covid-19-vaccine/story-vhD8r3PeNWX1nAxvBx4XEO.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.hindustantimes.com/world-news/the-woman-behind-the-oxford-astrazeneca-covid-19-vaccine/story-vhD8r3PeNWX1nAxvBx4XEO.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.hindustantimes.com/world-news/the-woman-behind-the-oxford-astrazeneca-covid-19-vaccine/story-vhD8r3PeNWX1nAxvBx4XEO.html</a></span></div></li><li id="https://www.bath.ac.uk/corporate-information/professor-dame-sarah-gilbert-oration/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bath.ac.uk/corporate-information/professor-dame-sarah-gilbert-oration/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bath.ac.uk/corporate-information/professor-dame-sarah-gilbert-oration/</a></span></div></li><li id="https://www.chch.ox.ac.uk/people/professor-dame-sarah-gilbert-dbe-frs" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.chch.ox.ac.uk/people/professor-dame-sarah-gilbert-dbe-frs" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.chch.ox.ac.uk/people/professor-dame-sarah-gilbert-dbe-frs</a></span></div></li><li id="https://www.kff.com/en/king-faisal-prize/professor-sarah-catherine-gilbert/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kff.com/en/king-faisal-prize/professor-sarah-catherine-gilbert/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kff.com/en/king-faisal-prize/professor-sarah-catherine-gilbert/</a></span></div></li><li id="https://www.science.org/content/author/sarah-gilbert-phd" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.science.org/content/author/sarah-gilbert-phd" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.science.org/content/author/sarah-gilbert-phd</a></span></div></li><li id="https://www.jenner.ac.uk/team/sarah-gilbert" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jenner.ac.uk/team/sarah-gilbert" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jenner.ac.uk/team/sarah-gilbert</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/22998622/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/22998622/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/22998622/</a></span></div></li><li id="https://onlinelibrary.wiley.com/doi/abs/10.1111/irv.12013" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://onlinelibrary.wiley.com/doi/abs/10.1111/irv.12013" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://onlinelibrary.wiley.com/doi/abs/10.1111/irv.12013</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7286676/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7286676/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7286676/</a></span></div></li><li id="https://www.nature.com/articles/s41598-019-52730-4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41598-019-52730-4" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41598-019-52730-4</a></span></div></li><li id="https://www.jenner.ac.uk/about/newsletter/jenner-institute-newsletter-autumn-2016/new-jenner-vaccine-programmes/outbreak-pathogens-new-mers-vaccine-programme" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jenner.ac.uk/about/newsletter/jenner-institute-newsletter-autumn-2016/new-jenner-vaccine-programmes/outbreak-pathogens-new-mers-vaccine-programme" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jenner.ac.uk/about/newsletter/jenner-institute-newsletter-autumn-2016/new-jenner-vaccine-programmes/outbreak-pathogens-new-mers-vaccine-programme</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/34751259/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/34751259/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/34751259/</a></span></div></li><li id="https://philanthropynewsdigest.org/news/other-sources/article/?id=14513735&amp;title=Scientists-test-world-first-Nipah-virus-vaccine" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://philanthropynewsdigest.org/news/other-sources/article/?id=14513735&amp;title=Scientists-test-world-first-Nipah-virus-vaccine" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://philanthropynewsdigest.org/news/other-sources/article/?id=14513735&amp;title=Scientists-test-world-first-Nipah-virus-vaccine</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/36543806/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/36543806/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/36543806/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/31026485/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/31026485/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/31026485/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/33654106/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/33654106/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/33654106/</a></span></div></li><li id="https://www.jenner.ac.uk/about/the-oxford-astrazeneca-covid-19-vaccine/ChAdOx-platform" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jenner.ac.uk/about/the-oxford-astrazeneca-covid-19-vaccine/ChAdOx-platform" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jenner.ac.uk/about/the-oxford-astrazeneca-covid-19-vaccine/ChAdOx-platform</a></span></div></li><li id="https://www.ukri.org/who-we-are/how-we-are-doing/research-outcomes-and-impact/mrc/the-story-behind-the-oxford-astrazeneca-covid-19-vaccine-success/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ukri.org/who-we-are/how-we-are-doing/research-outcomes-and-impact/mrc/the-story-behind-the-oxford-astrazeneca-covid-19-vaccine-success/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ukri.org/who-we-are/how-we-are-doing/research-outcomes-and-impact/mrc/the-story-behind-the-oxford-astrazeneca-covid-19-vaccine-success/</a></span></div></li><li id="https://www.ovg.ox.ac.uk/news/covid-19-vaccine-development" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ovg.ox.ac.uk/news/covid-19-vaccine-development" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ovg.ox.ac.uk/news/covid-19-vaccine-development</a></span></div></li><li id="https://www.jenner.ac.uk/about/news/covid-19-vaccine-development-at-the-jenner-institute" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jenner.ac.uk/about/news/covid-19-vaccine-development-at-the-jenner-institute" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jenner.ac.uk/about/news/covid-19-vaccine-development-at-the-jenner-institute</a></span></div></li><li id="https://www.ox.ac.uk/news/2023-09-18-oxford-and-liverpool-scientists-launch-new-vaccine-trial-middle-east-respiratory-1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ox.ac.uk/news/2023-09-18-oxford-and-liverpool-scientists-launch-new-vaccine-trial-middle-east-respiratory-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ox.ac.uk/news/2023-09-18-oxford-and-liverpool-scientists-launch-new-vaccine-trial-middle-east-respiratory-1</a></span></div></li><li id="https://www.medsci.ox.ac.uk/news/professor-sarah-gilbert-appointed-as-deputy-head-of-department" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.medsci.ox.ac.uk/news/professor-sarah-gilbert-appointed-as-deputy-head-of-department" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.medsci.ox.ac.uk/news/professor-sarah-gilbert-appointed-as-deputy-head-of-department</a></span></div></li><li id="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa2102214" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2102214" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa2102214</a></span></div></li><li id="https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html</a></span></div></li><li id="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3/fulltext</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0140673621004323" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0140673621004323" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0140673621004323</a></span></div></li><li id="https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa2105290" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2105290" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa2105290</a></span></div></li><li id="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32623-4/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32623-4/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32623-4/fulltext</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa2104840" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2104840" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa2104840</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0264410X21008720" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0264410X21008720" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0264410X21008720</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10676559/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10676559/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10676559/</a></span></div></li><li id="https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-8-september-2021_en.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-8-september-2021_en.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-8-september-2021_en.pdf</a></span></div></li><li id="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00762-5/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00762-5/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00762-5/fulltext</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0264410X24001270" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0264410X24001270" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0264410X24001270</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8315897/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8315897/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8315897/</a></span></div></li><li id="https://www.gov.uk/government/news/one-year-anniversary-of-uk-deploying-oxford-astrazeneca-vaccine" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.gov.uk/government/news/one-year-anniversary-of-uk-deploying-oxford-astrazeneca-vaccine" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.gov.uk/government/news/one-year-anniversary-of-uk-deploying-oxford-astrazeneca-vaccine</a></span></div></li><li id="https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-advances-mass-global-rollout-of-covid-19-vaccine-through-covax.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-advances-mass-global-rollout-of-covid-19-vaccine-through-covax.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-advances-mass-global-rollout-of-covid-19-vaccine-through-covax.html</a></span></div></li><li id="https://www.ox.ac.uk/news/2022-07-15-oxford-vaccine-saved-most-lives-its-first-year-rollout" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ox.ac.uk/news/2022-07-15-oxford-vaccine-saved-most-lives-its-first-year-rollout" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ox.ac.uk/news/2022-07-15-oxford-vaccine-saved-most-lives-its-first-year-rollout</a></span></div></li><li id="https://www.gavi.org/vaccineswork/how-effective-are-covid-19-vaccines-real-world" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.gavi.org/vaccineswork/how-effective-are-covid-19-vaccines-real-world" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.gavi.org/vaccineswork/how-effective-are-covid-19-vaccines-real-world</a></span></div></li><li id="https://www.astrazeneca.com/media-centre/medical-releases/vaxzevria-shown-in-expert-review-to-provide-equally-effective-protection-against-covid-19.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.astrazeneca.com/media-centre/medical-releases/vaxzevria-shown-in-expert-review-to-provide-equally-effective-protection-against-covid-19.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.astrazeneca.com/media-centre/medical-releases/vaxzevria-shown-in-expert-review-to-provide-equally-effective-protection-against-covid-19.html</a></span></div></li><li id="https://www.thelancet.com/article/S2213-2600%2824%2900179-6/abstract" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.thelancet.com/article/S2213-2600%2824%2900179-6/abstract" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.thelancet.com/article/S2213-2600%2824%2900179-6/abstract</a></span></div></li><li id="https://www.bbc.com/news/world-europe-56744474" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bbc.com/news/world-europe-56744474" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bbc.com/news/world-europe-56744474</a></span></div></li><li id="https://www.bhf.org.uk/informationsupport/heart-matters-magazine/news/coronavirus-and-your-health/astrazeneca-covid-vaccine" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bhf.org.uk/informationsupport/heart-matters-magazine/news/coronavirus-and-your-health/astrazeneca-covid-vaccine" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bhf.org.uk/informationsupport/heart-matters-magazine/news/coronavirus-and-your-health/astrazeneca-covid-vaccine</a></span></div></li><li id="https://www.cnn.com/2024/05/08/business/astrazeneca-covid-vaccine-withdrawal" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cnn.com/2024/05/08/business/astrazeneca-covid-vaccine-withdrawal" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cnn.com/2024/05/08/business/astrazeneca-covid-vaccine-withdrawal</a></span></div></li><li id="https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria</a></span></div></li><li id="https://www.the-independent.com/news/science/astrazeneca-covid-vaccine-withdraw-blood-clots-b2541291.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.the-independent.com/news/science/astrazeneca-covid-vaccine-withdraw-blood-clots-b2541291.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.the-independent.com/news/science/astrazeneca-covid-vaccine-withdraw-blood-clots-b2541291.html</a></span></div></li><li id="https://www.chartwellspeakers.com/speaker/sarah-gilbert/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.chartwellspeakers.com/speaker/sarah-gilbert/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.chartwellspeakers.com/speaker/sarah-gilbert/</a></span></div></li><li id="https://www.ox.ac.uk/news/2021-03-05-oxford-vaccine-creator-professor-sarah-gilbert-awarded-rsa-albert-medal" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ox.ac.uk/news/2021-03-05-oxford-vaccine-creator-professor-sarah-gilbert-awarded-rsa-albert-medal" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ox.ac.uk/news/2021-03-05-oxford-vaccine-creator-professor-sarah-gilbert-awarded-rsa-albert-medal</a></span></div></li><li id="https://kingfaisalprize.org/en/professor-sarah-catherine-gilbert/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://kingfaisalprize.org/en/professor-sarah-catherine-gilbert/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://kingfaisalprize.org/en/professor-sarah-catherine-gilbert/</a></span></div></li><li id="https://www.psi.ox.ac.uk/news-and-opinion/professor-dame-sarah-gilbert-awarded-freedom-of-the-city-of-london" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.psi.ox.ac.uk/news-and-opinion/professor-dame-sarah-gilbert-awarded-freedom-of-the-city-of-london" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.psi.ox.ac.uk/news-and-opinion/professor-dame-sarah-gilbert-awarded-freedom-of-the-city-of-london</a></span></div></li><li id="https://www.qub.ac.uk/research-centres/wwiem/News/QueensawardsBarcroftMedaltoProfessorwholeddevelopmentofOxfordvaccine.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.qub.ac.uk/research-centres/wwiem/News/QueensawardsBarcroftMedaltoProfessorwholeddevelopmentofOxfordvaccine.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.qub.ac.uk/research-centres/wwiem/News/QueensawardsBarcroftMedaltoProfessorwholeddevelopmentofOxfordvaccine.html</a></span></div></li><li id="https://www.psi.ox.ac.uk/news-and-opinion/sarah-gilbert-receives-royal-society-of-chemistry-honorary-fellowship" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.psi.ox.ac.uk/news-and-opinion/sarah-gilbert-receives-royal-society-of-chemistry-honorary-fellowship" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.psi.ox.ac.uk/news-and-opinion/sarah-gilbert-receives-royal-society-of-chemistry-honorary-fellowship</a></span></div></li><li id="https://www.facebook.com/woxsen/posts/we-are-honoured-to-confer-the-woxsen-luminary-award-for-outstanding-research-con/796123656403959/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.facebook.com/woxsen/posts/we-are-honoured-to-confer-the-woxsen-luminary-award-for-outstanding-research-con/796123656403959/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.facebook.com/woxsen/posts/we-are-honoured-to-confer-the-woxsen-luminary-award-for-outstanding-research-con/796123656403959/</a></span></div></li><li id="https://www.ox.ac.uk/news/2021-12-07-professor-dame-sarah-gilbert-delivers-44th-dimbleby-lecture" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ox.ac.uk/news/2021-12-07-professor-dame-sarah-gilbert-delivers-44th-dimbleby-lecture" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ox.ac.uk/news/2021-12-07-professor-dame-sarah-gilbert-delivers-44th-dimbleby-lecture</a></span></div></li><li id="https://www.bbc.co.uk/iplayer/episode/m0012b15/the-richard-dimbleby-lecture-dame-sarah-gilbert" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bbc.co.uk/iplayer/episode/m0012b15/the-richard-dimbleby-lecture-dame-sarah-gilbert" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bbc.co.uk/iplayer/episode/m0012b15/the-richard-dimbleby-lecture-dame-sarah-gilbert</a></span></div></li><li id="https://www.chch.ox.ac.uk/news/professor-dame-sarah-gilbert-delivers-second-500th-anniversary-lecture" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.chch.ox.ac.uk/news/professor-dame-sarah-gilbert-delivers-second-500th-anniversary-lecture" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.chch.ox.ac.uk/news/professor-dame-sarah-gilbert-delivers-second-500th-anniversary-lecture</a></span></div></li><li id="https://www.ucl.ac.uk/news/2024/nov/ucl-prize-lecture-its-very-exciting-time-be-vaccinologist" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ucl.ac.uk/news/2024/nov/ucl-prize-lecture-its-very-exciting-time-be-vaccinologist" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ucl.ac.uk/news/2024/nov/ucl-prize-lecture-its-very-exciting-time-be-vaccinologist</a></span></div></li><li id="https://www.lshtm.ac.uk/newsevents/events/vaccine-centre-annual-lecture-professor-dame-sarah-gilbert" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.lshtm.ac.uk/newsevents/events/vaccine-centre-annual-lecture-professor-dame-sarah-gilbert" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.lshtm.ac.uk/newsevents/events/vaccine-centre-annual-lecture-professor-dame-sarah-gilbert</a></span></div></li><li id="https://www.youtube.com/watch?v=7lJo0MqamFE" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.youtube.com/watch?v=7lJo0MqamFE" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.youtube.com/watch?v=7lJo0MqamFE</a></span></div></li><li id="https://www.dailymail.co.uk/news/article-9098411/Troubled-path-approval-Oxfords-vaccine-professors-jab-make-MILLIONS.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.dailymail.co.uk/news/article-9098411/Troubled-path-approval-Oxfords-vaccine-professors-jab-make-MILLIONS.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.dailymail.co.uk/news/article-9098411/Troubled-path-approval-Oxfords-vaccine-professors-jab-make-MILLIONS.html</a></span></div></li><li id="https://www.theguardian.com/society/2022/jun/26/vaccinologist-sarah-gilbert-vaxxers-astrazeneca-we-need-to-be-better-prepared-for-a-new-pandemic" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.theguardian.com/society/2022/jun/26/vaccinologist-sarah-gilbert-vaxxers-astrazeneca-we-need-to-be-better-prepared-for-a-new-pandemic" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.theguardian.com/society/2022/jun/26/vaccinologist-sarah-gilbert-vaxxers-astrazeneca-we-need-to-be-better-prepared-for-a-new-pandemic</a></span></div></li><li id="https://www.businessinsider.com/sarah-gilbert-children-astrazeneca-oxford-coronavirus-vaccine-trial-2020-11" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.businessinsider.com/sarah-gilbert-children-astrazeneca-oxford-coronavirus-vaccine-trial-2020-11" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.businessinsider.com/sarah-gilbert-children-astrazeneca-oxford-coronavirus-vaccine-trial-2020-11</a></span></div></li><li id="https://www.telegraph.co.uk/women/life/hackers-anti-vaxxers-giving-triplets-jab-meet-woman-behind-britains/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.telegraph.co.uk/women/life/hackers-anti-vaxxers-giving-triplets-jab-meet-woman-behind-britains/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.telegraph.co.uk/women/life/hackers-anti-vaxxers-giving-triplets-jab-meet-woman-behind-britains/</a></span></div></li></ol></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi" id="_R_" async=""></script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi\"}]\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Sarah_Gilbert\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Sarah_Gilbert\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Sarah_Gilbert\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T797a,"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"# Sarah Gilbert\n\n![Sarah Gilbert](./_assets_/Dr.Sarah_Gilbert.jpg)\nDame Sarah Catherine Gilbert DBE FRS FMedSci (born April 1962) is a British vaccinologist serving as the Saïd Professor of Vaccinology at the University of Oxford's Jenner Institute.[](https://www.ndm.ox.ac.uk/team/sarah-gilbert)[](https://royalsociety.org/people/sarah-gilbert-36200/) Her research centers on viral vectored vaccines designed to elicit robust T cell and B cell immune responses against infectious diseases, including influenza and emerging pathogens such as MERS coronavirus, Nipah virus, and Lassa virus.[](https://www.tropicalmedicine.ox.ac.uk/team/sarah-gilbert)[](https://www.ndm.ox.ac.uk/team/sarah-gilbert)\n\nIn January 2020, Gilbert became the Oxford Project Leader for ChAdOx1 nCoV-19, an adenovirus-vectored vaccine candidate against SARS-CoV-2 that was developed using pre-existing chimpanzee adenovirus platforms to enable rapid adaptation to the novel coronavirus.[](https://www.ndm.ox.ac.uk/team/sarah-gilbert)[](https://www.psi.ox.ac.uk/our-team/sarah-gilbert) This vaccine, partnered with AstraZeneca, underwent clinical trials demonstrating efficacy in preventing symptomatic COVID-19 and received emergency use authorization in over 170 countries, contributing to global vaccination efforts despite subsequent scrutiny over rare adverse events like vaccine-induced thrombotic thrombocytopenia.[](https://www.ndm.ox.ac.uk/team/sarah-gilbert)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8704023/) Gilbert's prior work on universal influenza vaccines and candidates for Ebola and malaria underscored the platform's versatility for pandemic preparedness.[](https://www.tropicalmedicine.ox.ac.uk/team/sarah-gilbert)[](https://www.ndm.ox.ac.uk/team/sarah-gilbert)\n\nFor her contributions, Gilbert has been honored with the Dame Commander of the Order of the British Empire, Fellowship of the Royal Society, and the Royal Society's Copley Medal awarded to the Oxford vaccine team, recognizing advancements in collaborative vaccine innovation.[](https://www.ox.ac.uk/news/2022-08-24-oxford-scientists-honoured-eight-royal-society-awards)[](https://royalsociety.org/people/sarah-gilbert-36200/) Her approach prioritizes empirical testing of vectored technologies to address viral threats through cellular immunity, distinct from traditional antibody-focused strategies.[](https://www.tropicalmedicine.ox.ac.uk/team/sarah-gilbert)\n\n## Biography\n\n### Early life\n\nSarah Catherine Gilbert was born in April 1962 in Kettering, Northamptonshire, England.[](https://www.bbc.com/news/uk-55043551)[](http://sunhakpeaceprize.org/en/laureates/laureates_view.php?idx=571)\n\nHer father worked as an office manager for a shoemaking company, and her mother was an English teacher; neither parent had a background in science, technology, engineering, or mathematics fields.[](https://www.bbc.com/news/uk-55043551)[](https://www.hindustantimes.com/world-news/the-woman-behind-the-oxford-astrazeneca-covid-19-vaccine/story-vhD8r3PeNWX1nAxvBx4XEO.html) Little is publicly documented about her childhood beyond these family circumstances, which were typical of mid-20th-century working-class households in the region.[](https://www.bbc.com/news/uk-55043551)\n\n### Education\n\nSarah Gilbert attended Kettering High School for Girls, where she developed an interest in medicine.[](https://www.bath.ac.uk/corporate-information/professor-dame-sarah-gilbert-oration/) She earned a Bachelor of Science degree in biological sciences, specializing in microbiology, from the University of East Anglia in 1983, graduating with first-class honors and receiving a prize for the highest academic achievement in her specialization.[](https://www.chch.ox.ac.uk/people/professor-dame-sarah-gilbert-dbe-frs)[](https://www.kff.com/en/king-faisal-prize/professor-sarah-catherine-gilbert/)[](https://www.science.org/content/author/sarah-gilbert-phd)\n\nGilbert completed her PhD at the University of Hull, focusing on molecular biology aspects relevant to virology.[](https://www.chch.ox.ac.uk/people/professor-dame-sarah-gilbert-dbe-frs)[](https://www.science.org/content/author/sarah-gilbert-phd) Following her doctorate, she pursued postdoctoral research, joining the University of Oxford in 1994 as a senior postdoctoral researcher in the Nuffield Department of Medicine.[](https://www.ndm.ox.ac.uk/team/sarah-gilbert)[](https://www.kff.com/en/king-faisal-prize/professor-sarah-catherine-gilbert/)\n\n## Scientific Career\n\n### Pre-COVID research on viral vaccines\n\nPrior to the COVID-19 pandemic, Sarah Gilbert focused on viral-vectored vaccines employing the replication-deficient chimpanzee adenovirus ChAdOx1 platform, designed to induce potent cellular (T-cell) and humoral (antibody) immune responses against challenging viral targets. This approach, refined through her work at the Jenner Institute since 2005, emphasized conserved antigens to achieve broader protection, drawing from earlier experience in malaria vaccine vectors but applied specifically to viruses like influenza and emerging pathogens.[](https://www.ndm.ox.ac.uk/team/sarah-gilbert)[](https://www.jenner.ac.uk/team/sarah-gilbert)\n\nGilbert led the Jenner Institute's influenza vaccine program, targeting a universal influenza vaccine to overcome limitations of strain-matched seasonal shots by focusing on T-cell responses to internal viral proteins. In a 2012 review, she outlined progress in viral-vectored strategies for eliciting cross-reactive immunity against diverse influenza strains, including preclinical data on ChAdOx1-expressing nucleoprotein and matrix protein antigens.[](https://pubmed.ncbi.nlm.nih.gov/22998622/) Her team advanced candidates into early clinical stages, with phase I trials demonstrating safety and immunogenicity in humans by inducing CD4+ and CD8+ T-cell responses durable beyond one year.[](https://onlinelibrary.wiley.com/doi/abs/10.1111/irv.12013)\n\nFor Middle East Respiratory Syndrome coronavirus (MERS-CoV), Gilbert's group developed the ChAdOx1 MERS vaccine, with preclinical studies from 2016 onward showing single-dose protection in mice and camels, including reduced lung viral loads by orders of magnitude and mitigation of pneumonia.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7286676/)[](https://www.nature.com/articles/s41598-019-52730-4) The platform's efficacy in animal models informed rapid adaptation for other coronaviruses, with phase I human trials initiated pre-2020 to assess safety in seronegative adults.[](https://www.jenner.ac.uk/about/newsletter/jenner-institute-newsletter-autumn-2016/new-jenner-vaccine-programmes/outbreak-pathogens-new-mers-vaccine-programme)[](https://pubmed.ncbi.nlm.nih.gov/34751259/)\n\nGilbert extended the ChAdOx1 vector to henipaviruses, initiating Nipah virus vaccine research in 2017, which progressed to preclinical demonstrations of survival in African green monkeys following lethal challenge, via strong neutralizing antibodies and T-cell responses.[](https://philanthropynewsdigest.org/news/other-sources/article/?id=14513735\u0026title=Scientists-test-world-first-Nipah-virus-vaccine)[](https://pubmed.ncbi.nlm.nih.gov/36543806/) For Lassa fever, her team engineered ChAdOx1 Lassa-GPC, with 2019 platform reviews and subsequent guinea pig studies confirming full protection against lethal Josiah strain challenge through robust cellular and humoral immunity.[](https://pubmed.ncbi.nlm.nih.gov/31026485/)[](https://pubmed.ncbi.nlm.nih.gov/33654106/) These efforts underscored Gilbert's emphasis on platforms enabling swift responses to outbreak threats, with manufacturing pipelines established for first-in-human testing.[](https://www.ndm.ox.ac.uk/team/sarah-gilbert)\n\n### Development of the Oxford-AstraZeneca COVID-19 vaccine\n\n![Dr. Sarah Gilbert](./_assets_/Dr.Sarah_Gilbert.jpg)  \nThe Oxford-AstraZeneca COVID-19 vaccine, designated ChAdOx1 nCoV-19, utilized a replication-deficient chimpanzee adenovirus vector platform (ChAdOx1) developed over two decades at the University of Oxford's Jenner Institute. This platform originated in the early 2000s under Professor Adrian Hill, adapting a chimpanzee adenovirus serotype Y25 by deleting genes essential for replication and incorporating a human adenovirus gene to facilitate manufacturing. Prior applications included vaccines against malaria, influenza, and Ebola, with the vector demonstrating safety in thousands of human subjects across age groups.[](https://www.jenner.ac.uk/about/the-oxford-astrazeneca-covid-19-vaccine/ChAdOx-platform)[](https://www.ukri.org/who-we-are/how-we-are-doing/research-outcomes-and-impact/mrc/the-story-behind-the-oxford-astrazeneca-covid-19-vaccine-success/)  \n\nSarah Gilbert, Professor of Vaccinology at the Jenner Institute, served as the project leader for adapting the ChAdOx1 platform to target SARS-CoV-2. On January 10, 2020, following the public release of the viral genome, Gilbert and her team—including Professors Andrew Pollard, Teresa Lambe, Adrian Hill, and Dr. Sandy Douglas—began designing the vaccine construct by inserting the gene encoding the SARS-CoV-2 spike protein into the ChAdOx1 vector. This approach leveraged prior experience with a MERS coronavirus vaccine using the same vector, which had proven capable of eliciting strong T-cell and antibody responses. The design aimed for a single-dose regimen to rapidly induce immunity, capitalizing on the vector's non-replicating nature and broad safety profile observed in previous trials.[](https://www.ovg.ox.ac.uk/news/covid-19-vaccine-development)[](https://www.ukri.org/who-we-are/how-we-are-doing/research-outcomes-and-impact/mrc/the-story-behind-the-oxford-astrazeneca-covid-19-vaccine-success/)[](https://www.jenner.ac.uk/about/news/covid-19-vaccine-development-at-the-jenner-institute)  \n\nPreclinical evaluation commenced promptly, with a laboratory version of the vaccine tested in mice by early February 2020, confirming robust immune responses against the spike protein. Funding from UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR), including a £2.6 million rapid response grant in March 2020, supported these investigations and preparation for human trials. The Jenner Institute's Viral Vector Core Facility and Clinical Biomanufacturing Facility enabled rapid production of the candidate for testing. In parallel, Oxford partnered with AstraZeneca in March 2020 to accelerate large-scale manufacturing and global distribution, ensuring no-profit commitments for the pandemic phase. By April 2020, sufficient material was available for the first human dosing in phase I/II trials.[](https://www.ukri.org/who-we-are/how-we-are-doing/research-outcomes-and-impact/mrc/the-story-behind-the-oxford-astrazeneca-covid-19-vaccine-success/)[](https://www.ovg.ox.ac.uk/news/covid-19-vaccine-development)[](https://www.jenner.ac.uk/about/the-oxford-astrazeneca-covid-19-vaccine/ChAdOx-platform)\n\n### Post-vaccine research and ongoing contributions\n\nFollowing the emergency authorization of the Oxford-AstraZeneca COVID-19 vaccine in late 2020, Sarah Gilbert has directed her efforts toward enhancing viral vectored vaccine platforms, with a focus on improving efficacy against emerging infectious diseases through stronger T cell and B cell responses.[](https://www.jenner.ac.uk/team/sarah-gilbert) At the Jenner Institute, University of Oxford, she has led advancements in chimpanzee adenovirus-vectored technologies, building on the ChAdOx1 vector used in the COVID-19 vaccine to target pathogens requiring robust cellular immunity.[](https://www.jenner.ac.uk/team/sarah-gilbert)\n\nIn September 2023, Gilbert's team initiated a Phase I clinical trial for a MERS-CoV vaccine employing the ChAdOx1 platform, in partnership with the University of Liverpool's Centre for Global Vaccine Research; the trial evaluates safety and immunogenicity in up to 50 healthy adults aged 18-55, aiming to address the high mortality rate of MERS outbreaks, which exceed 35% in confirmed cases.[](https://www.ox.ac.uk/news/2023-09-18-oxford-and-liverpool-scientists-launch-new-vaccine-trial-middle-east-respiratory-1) This project extends her prior work on MERS vaccine candidates, prioritizing rapid-deployment vaccines for coronaviruses with pandemic potential.[](https://www.ox.ac.uk/news/2023-09-18-oxford-and-liverpool-scientists-launch-new-vaccine-trial-middle-east-respiratory-1)\n\nGilbert continues to oversee development of next-generation influenza vaccines, including efforts toward a universal flu vaccine capable of broader strain coverage beyond annual seasonal updates, amid ongoing refinements to antigen design and vector stability.[](https://www.medsci.ox.ac.uk/news/professor-sarah-gilbert-appointed-as-deputy-head-of-department) Her portfolio also encompasses vaccines for other priority pathogens, such as Nipah virus, Lassa fever virus, and Crimean-Congo haemorrhagic fever virus, with preclinical and early-stage trials emphasizing cross-protective immunity.[](https://www.medsci.ox.ac.uk/news/professor-sarah-gilbert-appointed-as-deputy-head-of-department) In January 2025, she was appointed Deputy Head of the Jenner Institute, where she now coordinates multi-pathogen vaccine pipelines and technology optimizations to accelerate responses to future outbreaks.[](https://www.medsci.ox.ac.uk/news/professor-sarah-gilbert-appointed-as-deputy-head-of-department)\n\nThese initiatives reflect Gilbert's emphasis on proactive platform-based vaccine design, enabling faster adaptation to novel threats compared to traditional inactivated or protein subunit approaches, as evidenced by her group's track record in compressing development timelines from years to months during the COVID-19 response.[](https://www.ukri.org/who-we-are/how-we-are-doing/research-outcomes-and-impact/mrc/the-story-behind-the-oxford-astrazeneca-covid-19-vaccine-success/)\n\n## Vaccine-Specific Analysis\n\n### Clinical trials and efficacy data\n\nThe ChAdOx1 nCoV-19 (AZD1222) vaccine underwent phase 3 evaluation in randomized, placebo-controlled trials including COV002 (UK, n=11,734 analyzed for efficacy), COV003 (Brazil, n=4,228), and COV005 (South Africa, n=1,753 HIV-uninfected participants).[](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext) [](https://www.nejm.org/doi/full/10.1056/NEJMoa2102214) An interim pooled analysis across these trials, published in December 2020, reported overall efficacy of 70.4% (95% CI 54.8–80.6) against symptomatic COVID-19 at least 14 days after the second dose, with zero cases of hospitalization or severe disease in the vaccine arm (versus two severe cases and one death in placebo).[](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext) [](https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html)\n\nA subsequent pooled analysis of the same trials, focusing on dosing regimens, found efficacy of 66.7% (95% CI 57.4–74.0) more than 14 days after two full doses, with 84 symptomatic cases among 8,597 vaccine recipients versus 254 among 8,073 placebo recipients.[](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3/fulltext) Efficacy after a single standard dose was 76.0% (95% CI 59.3–85.9) from day 22 to day 90 post-vaccination, based on 53 cases in 2,141 vaccine recipients versus 91 in 2,227 placebo recipients during that period.[](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3/fulltext) Interval between doses influenced outcomes: two full doses yielded 55.1% efficacy (95% CI 33.0–69.9; 30 cases in 1,761 recipients) with less than 6 weeks spacing, rising to 81.3% (95% CI 60.3–91.2; 7 cases in 2,077 recipients) with more than 12 weeks spacing.[](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3/fulltext) [](https://www.sciencedirect.com/science/article/pii/S0140673621004323)\n\nEfficacy varied by SARS-CoV-2 variant. In the South African trial (February–April 2021 enrollment), where over 90% of sequenced cases were B.1.351 (beta variant), two doses showed 0% efficacy (95% CI –132.3 to 52.3; 23 cases in 717 vaccine recipients versus 28 in 750 placebo) against mild-to-moderate disease but 100% efficacy (95% CI –13.0 to 100) against severe or critical disease (zero events in vaccine arm versus two hospitalizations in placebo).[](https://www.nejm.org/doi/full/10.1056/NEJMoa2102214) [](https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1) A separate phase 3 trial in the US (n=32,449), using a 4-week interval, reported 74.0% overall efficacy (95% CI 65.7–80.5) against symptomatic disease, with 76 hospitalizations in the vaccine group versus 185 in placebo.[](https://www.nejm.org/doi/full/10.1056/NEJMoa2105290)\n\n### Safety profile and adverse events\n\nIn phase 3 clinical trials involving over 23,000 participants, the ChAdOx1 nCoV-19 vaccine demonstrated a favorable safety profile, with solicited adverse events primarily mild to moderate and resolving within a few days; these included injection-site pain (reported in 60-70% of recipients after the first dose), headache (50-60%), fatigue (50-60%), and myalgia (40-50%), occurring more frequently after the first dose than the second.[](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32623-4/fulltext) Unsolicited adverse events were similar between vaccine and control groups, and no vaccine-related deaths or hospitalizations due to anaphylaxis were observed.[](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32623-4/fulltext) Serious adverse events occurred at rates of 0.7 per 1000 in vaccine recipients versus 0.8 per 1000 in controls, with none deemed causally related to the vaccine.[](https://www.nejm.org/doi/full/10.1056/NEJMoa2105290)\n\nPost-authorization surveillance identified rare but serious adverse events, notably thrombosis with thrombocytopenia syndrome (TTS), a condition involving venous or arterial thrombosis combined with low platelet counts and anti-platelet factor 4 antibodies, typically emerging 5-30 days after vaccination.[](https://www.nejm.org/doi/full/10.1056/NEJMoa2104840) Incidence rates varied by age and sex, estimated at 2-3 cases per 100,000 doses overall, but up to 10-15 per 100,000 in women under 60 years in some European cohorts, with a case fatality rate of approximately 20-25%.[](https://www.sciencedirect.com/science/article/pii/S0264410X21008720) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC10676559/) This led to temporary suspensions and age-based restrictions in several countries, though regulatory reviews, including by the European Medicines Agency (EMA), confirmed no overall increase in thrombosis risk beyond TTS and affirmed that benefits exceeded risks given COVID-19's higher thrombotic complications.[](https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-8-september-2021_en.pdf) [](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00762-5/fulltext)\n\nOther rare events included Guillain-Barré syndrome (GBS), with EMA reporting 227 cases following about 51 million doses by mid-2021, prompting its addition to product labeling, though causality remains unconfirmed and rates were not elevated beyond background levels in some analyses.[](https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-8-september-2021_en.pdf) No significant signals for myocarditis or pericarditis emerged, unlike with mRNA vaccines.[](https://www.sciencedirect.com/science/article/pii/S0264410X24001270) Large-scale observational studies post-rollout corroborated trial findings, with serious adverse events remaining infrequent (under 1 per 10,000 doses) and self-resolving common side effects dominating reports.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8315897/)\n\n### Global rollout, impact, and withdrawal\n\nThe Oxford–AstraZeneca vaccine, marketed as Vaxzevria or Covishield in various regions, received emergency authorization in the United Kingdom on December 30, 2020, marking the start of its global rollout.[](https://www.gov.uk/government/news/one-year-anniversary-of-uk-deploying-oxford-astrazeneca-vaccine) By March 2021, initial doses began arriving in low- and middle-income countries via the COVAX Facility, with AstraZeneca committing to supply hundreds of millions of doses at cost.[](https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-advances-mass-global-rollout-of-covid-19-vaccine-through-covax.html) Over 2.5 billion doses were administered worldwide by early 2022, reaching more than 170 countries, particularly aiding equitable access in regions with limited mRNA vaccine availability.[](https://www.gov.uk/government/news/one-year-anniversary-of-uk-deploying-oxford-astrazeneca-vaccine)[](https://www.ukri.org/who-we-are/how-we-are-doing/research-outcomes-and-impact/mrc/the-story-behind-the-oxford-astrazeneca-covid-19-vaccine-success/)\n\nReal-world studies demonstrated substantial public health impact, with the vaccine estimated to have averted 6.3 million deaths in its first year of deployment (December 2020 to December 2021), outperforming other vaccines in global reach during that period due to its distribution to lower-income settings.[](https://www.ox.ac.uk/news/2022-07-15-oxford-vaccine-saved-most-lives-its-first-year-rollout) Effectiveness against severe outcomes remained high, at 92% for hospitalization prevention after two doses in early variants, comparable to mRNA vaccines in preventing deaths and hospital admissions per expert reviews of observational data.[](https://www.gavi.org/vaccineswork/how-effective-are-covid-19-vaccines-real-world)[](https://www.astrazeneca.com/media-centre/medical-releases/vaxzevria-shown-in-expert-review-to-provide-equally-effective-protection-against-covid-19.html) Broader modeling across 185 countries indicated vaccines like Oxford–AstraZeneca contributed to a 59% reduction in COVID-19 mortality in participating nations through March 2023, though efficacy waned against later variants without boosters.[](https://www.thelancet.com/article/S2213-2600%2824%2900179-6/abstract)\n\nDeployment faced interruptions in several countries starting March 2021 due to rare cases of thrombosis with thrombocytopenia syndrome (TTS), prompting pauses in Denmark (fully ceased April 2021), Norway, and others, with incidence rates of 1–2 per 100,000 doses primarily in younger adults.[](https://www.bbc.com/news/world-europe-56744474) The United Kingdom discontinued routine use by winter 2021, favoring mRNA options for younger groups amid variant shifts.[](https://www.bhf.org.uk/informationsupport/heart-matters-magazine/news/coronavirus-and-your-health/astrazeneca-covid-vaccine) In May 2024, AstraZeneca initiated global withdrawal of Vaxzevria's marketing authorizations, citing a surplus of updated vaccines targeting new variants and resulting low demand as the primary commercial rationale, rather than safety concerns.[](https://www.cnn.com/2024/05/08/business/astrazeneca-covid-vaccine-withdrawal)[](https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria) The European Medicines Agency confirmed the EU authorization's removal at the company's request for these reasons, following earlier admissions in legal proceedings of a plausible causal link to TTS.[](https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria)[](https://www.the-independent.com/news/science/astrazeneca-covid-vaccine-withdraw-blood-clots-b2541291.html)\n\n## Recognition and Honors\n\n### Major awards and titles\n\nGilbert was appointed **Dame Commander of the Order of the British Empire (DBE)** in the 2021 New Year Honours for services to scientific research and development in the response to the COVID-19 pandemic.[](https://www.chartwellspeakers.com/speaker/sarah-gilbert/) In March 2021, she received the **Albert Medal** from the Royal Society of Arts, Manufactures and Commerce, recognizing her leadership in developing the Oxford-AstraZeneca COVID-19 vaccine as a model of collaborative innovation for global health.[](https://www.ox.ac.uk/news/2021-03-05-oxford-vaccine-creator-professor-sarah-gilbert-awarded-rsa-albert-medal)\n\nLater in 2021, Gilbert was awarded the **Princess of Asturias Award for Technical \u0026 Scientific Research** (shared with other Oxford vaccine developers) for advancing viral vector vaccine platforms against multiple pathogens, including SARS-CoV-2.[](https://www.chartwellspeakers.com/speaker/sarah-gilbert/) She also received the **Royal Society of Medicine Gold Medal** that year for her contributions to medical research, particularly in vaccinology.[](https://www.kff.com/en/king-faisal-prize/professor-sarah-catherine-gilbert/) In recognition of her vaccine work's global impact, she was named a laureate of the **Sunhak Peace Prize** in 2022.[](http://sunhakpeaceprize.org/en/laureates/laureates_view.php?idx=571)\n\nIn 2023, Gilbert received the **King Faisal International Prize for Medicine** for pioneering viral vector vaccines applied to diseases such as malaria, Ebola, influenza, MERS, and COVID-19.[](https://kingfaisalprize.org/en/professor-sarah-catherine-gilbert/) That October, she was granted the **Freedom of the City of London** for her role in developing an effective, scalable COVID-19 vaccine credited with saving over six million lives worldwide.[](https://www.psi.ox.ac.uk/news-and-opinion/professor-dame-sarah-gilbert-awarded-freedom-of-the-city-of-london) In March 2021, she was awarded the **Barcroft Medal** by Queen's University Belfast for outstanding achievements in medical research.[](https://www.qub.ac.uk/research-centres/wwiem/News/QueensawardsBarcroftMedaltoProfessorwholeddevelopmentofOxfordvaccine.html)\n\nMore recently, in April 2025, Gilbert was elected an **Honorary Fellow** of the Royal Society of Chemistry for co-developing the Oxford-AstraZeneca vaccine.[](https://www.psi.ox.ac.uk/news-and-opinion/sarah-gilbert-receives-royal-society-of-chemistry-honorary-fellowship) In August 2025, she received the **Woxsen Luminary Award for Outstanding Research Contributions** from Woxsen University.[](https://www.facebook.com/woxsen/posts/we-are-honoured-to-confer-the-woxsen-luminary-award-for-outstanding-research-con/796123656403959/)\n\n### Public lectures and media engagements\n\nProfessor Dame Sarah Gilbert has delivered several prominent public lectures on vaccine development and pandemic preparedness, often highlighting the role of viral vector technologies and the need for proactive global responses to emerging threats. These engagements underscore her advocacy for sustained investment in platform-based vaccine platforms, drawing from her experience with the ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca).[](https://www.ox.ac.uk/news/2021-12-07-professor-dame-sarah-gilbert-delivers-44th-dimbleby-lecture)\n\nIn 2021, Gilbert presented the 44th Richard Dimbleby Lecture, titled \"Vaccine vs the Virus: This race, and the next one\", broadcast by the BBC, in which she detailed the rapid adaptation of prior \"Disease X\" research to COVID-19, the logistical challenges overcome for emergency authorization by the UK's MHRA on December 30, 2020, and the imperative for enhanced manufacturing capacity to address variants like Omicron.[](https://www.ox.ac.uk/news/2021-12-07-professor-dame-sarah-gilbert-delivers-44th-dimbleby-lecture)[](https://www.bbc.co.uk/iplayer/episode/m0012b15/the-richard-dimbleby-lecture-dame-sarah-gilbert)\n\nOn June 25, 2025, she delivered the second 500th Anniversary Lecture for Christ Church, Oxford, at Oxford Town Hall, titled \"Preparation and pandemics: confronting new threats\", chaired by BBC Health Editor Hugh Pym; the talk covered university-industry partnerships, work on viruses like Nipah, and key lessons from COVID-19 for mitigating future outbreaks.[](https://www.chch.ox.ac.uk/news/professor-dame-sarah-gilbert-delivers-second-500th-anniversary-lecture)\n\nGilbert gave the 2024 UCL Prize Lecture in Life and Medical Sciences on November 14, titled \"Vaccine development during and after the pandemic\", where she described assembling multidisciplinary teams for ChAdOx1, its advantages for low-income countries due to non-frozen storage and its estimated millions of lives saved in the first year post-rollout, while stressing regulatory hurdles and the urgency of preparing for subsequent pandemics.[](https://www.ucl.ac.uk/news/2024/nov/ucl-prize-lecture-its-very-exciting-time-be-vaccinologist)\n\nShe has also spoken at the London School of Hygiene \u0026 Tropical Medicine's Vaccine Centre Annual Lecture on vaccines targeting outbreak pathogens, including Ebola in 2014 and the conceptual \"Disease X\" in 2020, followed by a public Q\u0026A to address ongoing post-pandemic requirements.[](https://www.lshtm.ac.uk/newsevents/events/vaccine-centre-annual-lecture-professor-dame-sarah-gilbert)\n\nIn media engagements, Gilbert has appeared in interviews and conferences, such as the Doherty Institute's 2023 media event on COVID-19 vaccines and discussions with outlets like BBC Radio, emphasizing collaborative successes and communication challenges during crises.[](https://www.youtube.com/watch?v=7lJo0MqamFE)\n\n## Personal Life\n\n### Family and private interests\n\nSarah Gilbert is married to Rob Blundell, a fellow scientist.[](https://www.dailymail.co.uk/news/article-9098411/Troubled-path-approval-Oxfords-vaccine-professors-jab-make-MILLIONS.html)[](https://www.theguardian.com/society/2022/jun/26/vaccinologist-sarah-gilbert-vaxxers-astrazeneca-we-need-to-be-better-prepared-for-a-new-pandemic) The couple has three children, triplets consisting of daughters Susannah and Caitlin and son Freddie.[](https://www.businessinsider.com/sarah-gilbert-children-astrazeneca-oxford-coronavirus-vaccine-trial-2020-11)[](https://www.dailymail.co.uk/news/article-9098411/Troubled-path-approval-Oxfords-vaccine-professors-jab-make-MILLIONS.html) All three children pursued studies in biochemistry, with Susannah and Caitlin attending the University of Oxford and Freddie enrolling at the University of Manchester.[](https://www.businessinsider.com/sarah-gilbert-children-astrazeneca-oxford-coronavirus-vaccine-trial-2020-11) In late 2020, the triplets volunteered as participants in phase III clinical trials of the Oxford-AstraZeneca COVID-19 vaccine, reflecting a family-wide commitment to scientific advancement amid the pandemic.[](https://www.businessinsider.com/sarah-gilbert-children-astrazeneca-oxford-coronavirus-vaccine-trial-2020-11)[](https://www.telegraph.co.uk/women/life/hackers-anti-vaxxers-giving-triplets-jab-meet-woman-behind-britains/) Gilbert and her family reside in Oxford.[](https://www.theguardian.com/society/2022/jun/26/vaccinologist-sarah-gilbert-vaxxers-astrazeneca-we-need-to-be-better-prepared-for-a-new-pandemic) Little public information exists regarding her personal hobbies or non-professional pursuits, consistent with her emphasis on privacy outside of her scientific work."])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761882062465,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"Sarah Gilbert - Nuffield Department of Medicine - University of Oxford\",\"description\":\"She leads work on influenza vaccine development as well as vaccines for many different emerging pathogens, including Nipah virus, MERS, and Lassa virus.\",\"url\":\"https://www.ndm.ox.ac.uk/team/sarah-gilbert\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"Dame Sarah Gilbert DBE FMedSci FRS - Royal Society\",\"description\":\"In 2020 Professor Gilbert became the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus SARS-CoV-2. This vaccine, tested by ...\",\"url\":\"https://royalsociety.org/people/sarah-gilbert-36200/\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"Sarah Gilbert - The Jenner Institute\",\"description\":\"Her chief research interest is the development of viral vectored vaccines that work by inducing strong and protective T and B cell responses.\",\"url\":\"https://www.tropicalmedicine.ox.ac.uk/team/sarah-gilbert\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"Sarah Gilbert - Pandemic Sciences Institute - University of Oxford\",\"description\":\"In 2020 Professor Gilbert became the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus SARS-CoV-2. This vaccine, tested by ...\",\"url\":\"https://www.psi.ox.ac.uk/our-team/sarah-gilbert\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"Who funded the research behind the Oxford–AstraZeneca COVID ...\",\"description\":\"The Oxford–AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19, Vaxzevira or Covishield) builds on two decades of research and development (R\u0026D) into chimpanzee ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8704023/\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"Oxford scientists honoured with eight Royal Society Awards\",\"description\":\"Aug 24, 2022 · Accepting the Copley Medal on behalf of the team, Professor Dame Sarah Gilbert DBE, Saïd Professor of Vaccinology at the University of Oxford, ...Missing:  virologist biography\",\"url\":\"https://www.ox.ac.uk/news/2022-08-24-oxford-scientists-honoured-eight-royal-society-awards\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"Prof Sarah Gilbert: The woman who designed the Oxford vaccine\",\"description\":\"Nov 23, 2020 · Born in Kettering, Northamptonshire in April 1962, Sarah Gilbert's father worked in the shoe business while her mother was an English ...Missing:  family | Show results with:family\",\"url\":\"https://www.bbc.com/news/uk-55043551\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"Laureates - LAUREATES - Sunhak Peace Prize\",\"description\":\"Professor Dame Sarah Gilbert has been working for over 25 years on designing vaccines against infectious diseases such as Middle East Respiratory Syndrome (MERS) ...\",\"url\":\"http://sunhakpeaceprize.org/en/laureates/laureates_view.php?idx=571\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"The woman behind the Oxford-AstraZeneca Covid-19 vaccine\",\"description\":\"Nov 24, 2020 · Professor Sarah Gilbert was born in Kettering, Northamptonshire in April 1962, both her parents were not in STEM fields.\",\"url\":\"https://www.hindustantimes.com/world-news/the-woman-behind-the-oxford-astrazeneca-covid-19-vaccine/story-vhD8r3PeNWX1nAxvBx4XEO.html\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"Professor Dame Sarah Gilbert: oration - University of Bath\",\"description\":\"In 2020 Professor Gilbert became the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus SARS-CoV-2, widely known as COVID-19.\",\"url\":\"https://www.bath.ac.uk/corporate-information/professor-dame-sarah-gilbert-oration/\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"Professor Dame Sarah Gilbert DBE FRS - Christ Church, Oxford\",\"description\":\"Having come to Oxford as a Senior Molecular Biologist, I was appointed University Research Lecturer in 1999, Reader in Vaccinology in 2004, Jenner Investigator ...Missing:  childhood | Show results with:childhood\",\"url\":\"https://www.chch.ox.ac.uk/people/professor-dame-sarah-gilbert-dbe-frs\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"Professor Sarah Catherine Gilbert - King Faisal Foundation\",\"description\":\"She was awarded the prize in recognition of her development of innovative vaccine technologies and applying them to malaria, Ebola, influenza, MERS and lately ...Missing:  developer achievements\",\"url\":\"https://www.kff.com/en/king-faisal-prize/professor-sarah-catherine-gilbert/\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"Sarah Gilbert, Ph.D. | Science | AAAS\",\"description\":\"Gilbert completed her undergraduate studies at the University of East Anglia and her doctoral degree at the University of Hull. ... Oxford University in 1994 ...\",\"url\":\"https://www.science.org/content/author/sarah-gilbert-phd\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"Sarah Gilbert - The Jenner Institute\",\"description\":\"Her chief research interest is the development of viral vectored vaccines that work by inducing strong and protective T and B cell responses.\",\"url\":\"https://www.jenner.ac.uk/team/sarah-gilbert\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"Advances in the development of universal influenza vaccines\",\"description\":\"Advances in the development of universal influenza vaccines ... Affiliation. 1 Jenner Institute, University of Oxford, Oxford, UK. sarah.gilbert@ndm.ox.ac.uk.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/22998622/\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"Advances in the development of universal influenza vaccines - 2013\",\"description\":\"Sep 24, 2012 · Please cite this paper as: Sarah C. Gilbert. (2012) Advances in the development of universal influenza vaccines. Influenza and Other ...\",\"url\":\"https://onlinelibrary.wiley.com/doi/abs/10.1111/irv.12013\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"A single dose of ChAdOx1 MERS provides protective immunity ... - NIH\",\"description\":\"The vaccine protected against respiratory injury and pneumonia and reduced viral load in lung tissue by several orders of magnitude. MERS-CoV replication in ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7286676/\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 ...\",\"description\":\"Nov 8, 2019 · MERS-CoV seronegative and seropositive camels received a single intramuscular dose of ChAdOx1 MERS, a replication-deficient adenoviral vectored vaccine.\",\"url\":\"https://www.nature.com/articles/s41598-019-52730-4\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"Outbreak Pathogens: New MERS Vaccine Programme\",\"description\":\"A research group led by Professor Sarah Gilbert at the Jenner Institute in Oxford has developed a vaccine against MERS, utilising the Institute's proprietary ...\",\"url\":\"https://www.jenner.ac.uk/about/newsletter/jenner-institute-newsletter-autumn-2016/new-jenner-vaccine-programmes/outbreak-pathogens-new-mers-vaccine-programme\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in ...\",\"description\":\"We assessed the safety and immunogenicity of the ChAdOx1 MERS vaccine in a phase 1b trial in healthy Middle Eastern adults. Method: MERS002 is an open-label, ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/34751259/\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"Scientists test world-first Nipah virus vaccine\",\"description\":\"Jan 10, 2024 · Covid vaccine developer Professor Dame Sarah Gilbert said that work on the Nipah vaccine started in 2017 and was paused during the Covid-19 ...\u003c|separator|\u003e\",\"url\":\"https://philanthropynewsdigest.org/news/other-sources/article/?id=14513735\u0026title=Scientists-test-world-first-Nipah-virus-vaccine\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh ...\",\"description\":\"Dec 21, 2022 · ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys · Authors · Affiliations.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/36543806/\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"Vaccine platforms for the prevention of Lassa fever - PubMed\",\"description\":\"Apr 23, 2019 · Currently, there are no licensed vaccines to protect against LASV infection. Although numerous candidates have demonstrated efficacy in animal models.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/31026485/\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and ...\",\"description\":\"Mar 2, 2021 · ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/33654106/\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"Development of the ChAdOx vaccine platform - The Jenner Institute\",\"description\":\"The Jenner initiated a project to produce its own chimpanzee adenovirus vaccine platform 'in house', giving it the freedom to apply the promising technology to ...\",\"url\":\"https://www.jenner.ac.uk/about/the-oxford-astrazeneca-covid-19-vaccine/ChAdOx-platform\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"The story behind the Oxford-AstraZeneca COVID-19 vaccine success\",\"description\":\"Jul 2, 2024 · Professor Sarah Gilbert describes the process. The story behind the first successful clinical trial results showing the vaccine was effective, ...\",\"url\":\"https://www.ukri.org/who-we-are/how-we-are-doing/research-outcomes-and-impact/mrc/the-story-behind-the-oxford-astrazeneca-covid-19-vaccine-success/\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"COVID-19 vaccine development\",\"description\":\"Mar 18, 2020 · A team in Oxford led by Prof. Sarah Gilbert, Prof. Andrew Pollard, Prof. Teresa Lambe, Dr Sandy Douglas and Prof. Adrian Hill started work ...\",\"url\":\"https://www.ovg.ox.ac.uk/news/covid-19-vaccine-development\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"COVID-19 vaccine development - The Jenner Institute\",\"description\":\"Mar 18, 2020 · Gilbert and team have previously developed a vaccine for another human coronavirus disease, which is Middle East Respiratory Syndrome (MERS), ...\",\"url\":\"https://www.jenner.ac.uk/about/news/covid-19-vaccine-development-at-the-jenner-institute\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"Oxford and Liverpool scientists launch new vaccine trial for Middle ...\",\"description\":\"Sep 18, 2023 · Vaccine developed by Professor Dame Sarah Gilbert uses same ChAdOx1 platform technology as Oxford/AstraZeneca COVID-19 vaccine. A new clinical ...\",\"url\":\"https://www.ox.ac.uk/news/2023-09-18-oxford-and-liverpool-scientists-launch-new-vaccine-trial-middle-east-respiratory-1\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"Professor Sarah Gilbert appointed as Deputy Head of Department\",\"description\":\"Jan 13, 2025 · Professor Gilbert is currently working on vaccine technology improvements, and leading vaccine development for influenza and several emerging ...\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://www.medsci.ox.ac.uk/news/professor-sarah-gilbert-appointed-as-deputy-head-of-department\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B ...\",\"description\":\"Mar 16, 2021 · A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant.\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa2102214\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"AZD1222 vaccine met primary efficacy endpoint in preventing ...\",\"description\":\"Nov 23, 2020 · The vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported.\",\"url\":\"https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"Articles Single-dose administration and the influence of the timing of ...\",\"description\":\"Vaccine efficacy after two standard doses was 55·1% (95% CI 33·0–69·9) with an interval of less than 6 weeks and 81·3% (60·3–91·2) when more than 12 weeks apart ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0140673621004323\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 ...\",\"description\":\"Feb 12, 2021 · Conclusions A two-dose regimen of ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however, VE ...\",\"url\":\"https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid ...\",\"description\":\"Sep 29, 2021 · In a diverse adult population of more than 32,000 participants, two doses of AZD1222 administered 4 weeks apart were 74% efficacious overall at ...\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa2105290\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination\",\"description\":\"Apr 9, 2021 · To date, this reaction has been reported only with the ChAdOx1 nCov-19 vaccine, which has been used in approximately 25% of vaccine recipients ...\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa2104840\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"Thrombosis with Thrombocytopenia Syndrome (TTS) following ...\",\"description\":\"Aug 9, 2021 · The AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine is associated with Thrombosis with Thrombocytopenia Syndrome (TTS) in 3/100,000 ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0264410X21008720\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"ChAdOx1 nCoV-19 Vaccine and Thrombosis with ...\",\"description\":\"Several vaccine-induced thrombotic thrombocytopenia syndrome (VITTS) cases have been reported after the ChAdOx1 nCov-19 vaccination.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10676559/\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"[PDF] COVID-19 vaccine safety update - European Medicines Agency\",\"description\":\"Sep 8, 2021 · The product information will be updated with. Guillain-Barré syndrome (GBS) as a side effect of Vaxzevria. Pain in legs and arms or stomach and.\",\"url\":\"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-8-september-2021_en.pdf\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"COVID-19 vaccines and adverse events of special interest\",\"description\":\"Apr 2, 2024 · This study aimed to evaluate the risk of adverse events of special interest (AESI) following COVID-19 vaccination from 10 sites across eight countries.\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0264410X24001270\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"Evaluation of the safety profile of COVID-19 vaccines: a rapid review\",\"description\":\"Reporting rates of adverse events from post-authorization observational studies were similar to results from clinical trials.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8315897/\",\"favicon\":\"\"},{\"id\":\"44\",\"title\":\"One year anniversary of UK deploying Oxford-AstraZeneca vaccine\",\"description\":\"Jan 4, 2022 · 2.5 billion doses of the at-cost and UK-made vaccine have been administered across the world.Missing:  global | Show results with:global\",\"url\":\"https://www.gov.uk/government/news/one-year-anniversary-of-uk-deploying-oxford-astrazeneca-vaccine\",\"favicon\":\"\"},{\"id\":\"45\",\"title\":\"AstraZeneca advances mass global rollout of COVID-19 vaccine ...\",\"description\":\"Mar 2, 2021 · The first of many millions of doses of AstraZeneca's COVID-19 vaccine have begun arriving in low and middle-income countries across the world ...Missing:  timeline | Show results with:timeline\",\"url\":\"https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-advances-mass-global-rollout-of-covid-19-vaccine-through-covax.html\",\"favicon\":\"\"},{\"id\":\"46\",\"title\":\"Oxford vaccine saved most lives in its first year of rollout\",\"description\":\"Jul 15, 2022 · 'We started developing this method and the network to deliver it from February 2020, and AstraZeneca kept expanding that network from May 2020.Missing:  ChAdOx1 | Show results with:ChAdOx1\",\"url\":\"https://www.ox.ac.uk/news/2022-07-15-oxford-vaccine-saved-most-lives-its-first-year-rollout\",\"favicon\":\"\"},{\"id\":\"47\",\"title\":\"How effective are COVID-19 vaccines in the real-world?\",\"description\":\"Jul 23, 2021 · It found that former was 96% effective against hospitalisation after 2 doses, whereas the Oxford/AstraZeneca vaccine was 92% effective against ...\",\"url\":\"https://www.gavi.org/vaccineswork/how-effective-are-covid-19-vaccines-real-world\",\"favicon\":\"\"},{\"id\":\"48\",\"title\":\"Vaxzevria shown in expert review to provide equally effective ...\",\"description\":\"Jul 13, 2022 · Based on model outcomes Vaxzevria is estimated to have helped save over 6 million lives between 08 December 2020 and 08 December 2021.5. Notes.\",\"url\":\"https://www.astrazeneca.com/media-centre/medical-releases/vaxzevria-shown-in-expert-review-to-provide-equally-effective-protection-against-covid-19.html\",\"favicon\":\"\"},{\"id\":\"49\",\"title\":\"Estimated number of lives directly saved by COVID-19 vaccination ...\",\"description\":\"Between December, 2020, and March, 2023, in 34 of 54 CAT included in the analysis, COVID-19 vaccines reduced deaths by 59% overall (CAT range 17–82%), ...\",\"url\":\"https://www.thelancet.com/article/S2213-2600%2824%2900179-6/abstract\",\"favicon\":\"\"},{\"id\":\"50\",\"title\":\"AstraZeneca vaccine: Denmark stops rollout completely - BBC\",\"description\":\"Apr 14, 2021 · Denmark has ceased giving the Oxford-AstraZeneca Covid vaccine amid concerns about rare cases of blood clots, the first European country to ...\",\"url\":\"https://www.bbc.com/news/world-europe-56744474\",\"favicon\":\"\"},{\"id\":\"51\",\"title\":\"AstraZeneca Covid vaccine: safety and side effects - BHF\",\"description\":\"No, the UK government stopped using the AstraZeneca Covid-19 vaccine in winter 2021. In May 2024, AstraZeneca withdrew the vaccine, now called Vaxzevria, ...\",\"url\":\"https://www.bhf.org.uk/informationsupport/heart-matters-magazine/news/coronavirus-and-your-health/astrazeneca-covid-vaccine\",\"favicon\":\"\"},{\"id\":\"52\",\"title\":\"AstraZeneca withdraws Covid-19 vaccine, citing low demand - CNN\",\"description\":\"May 8, 2024 · AstraZeneca is withdrawing its highly successful coronavirus vaccine, citing the availability of a plethora of new shots that has led to a decline in demand.\",\"url\":\"https://www.cnn.com/2024/05/08/business/astrazeneca-covid-vaccine-withdrawal\",\"favicon\":\"\"},{\"id\":\"53\",\"title\":\"Vaxzevria (previously COVID-19 Vaccine AstraZeneca)\",\"description\":\"The withdrawal was at the request of the marketing authorisation holder, AstraZeneca ... discontinue the marketing of the product for commercial reasons.\",\"url\":\"https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria\",\"favicon\":\"\"},{\"id\":\"54\",\"title\":\"AstraZeneca withdraws Covid vaccine after admitting it can cause ...\",\"description\":\"May 8, 2024 · The withdrawal was due to a “surplus of available updated vaccines” against new variants of the novel coronavirus, the company said. The ...\",\"url\":\"https://www.the-independent.com/news/science/astrazeneca-covid-vaccine-withdraw-blood-clots-b2541291.html\",\"favicon\":\"\"},{\"id\":\"55\",\"title\":\"Sarah Gilbert - Leading Vaccinologist - Chartwell Speakers\",\"description\":\"Sarah Gilbert DBE is the Saïd Professor of Vaccinology at the University of Oxford who led the development of the Oxford-AstraZeneca COVID-19 vaccine.\",\"url\":\"https://www.chartwellspeakers.com/speaker/sarah-gilbert/\",\"favicon\":\"\"},{\"id\":\"56\",\"title\":\"Oxford vaccine creator Professor Sarah Gilbert awarded RSA Albert ...\",\"description\":\"Mar 5, 2021 · Professor Gilbert receives the 2021 honour for her services to collaborative innovation for the global common good. She is the 156th recipient ...Missing:  developer achievements\",\"url\":\"https://www.ox.ac.uk/news/2021-03-05-oxford-vaccine-creator-professor-sarah-gilbert-awarded-rsa-albert-medal\",\"favicon\":\"\"},{\"id\":\"57\",\"title\":\"Professor Dame Sarah Catherine Gilbert - King Faisal Prize\",\"description\":\"Professor Sarah Catherine Gilbert was awarded the prize for developing innovative vaccine technologies and applying them to malaria, Ebola, influenza, MERS and ...\",\"url\":\"https://kingfaisalprize.org/en/professor-sarah-catherine-gilbert/\",\"favicon\":\"\"},{\"id\":\"58\",\"title\":\"Professor Dame Sarah Gilbert awarded Freedom of the City of London\",\"description\":\"Oct 5, 2023 · This award recognises my work to develop an effective, affordable vaccine against COVID-19 that has now saved more than six million lives ...\",\"url\":\"https://www.psi.ox.ac.uk/news-and-opinion/professor-dame-sarah-gilbert-awarded-freedom-of-the-city-of-london\",\"favicon\":\"\"},{\"id\":\"59\",\"title\":\"Queen's awards Barcroft Medal to Professor who led development of ...\",\"description\":\"Mar 10, 2021 · Throughout her career, Professor Gilbert has made and tested vaccines for malaria, influenza, and emerging pathogens, such as Nipah and MERS.Missing:  developer | Show results with:developer\u003c|separator|\u003e\",\"url\":\"https://www.qub.ac.uk/research-centres/wwiem/News/QueensawardsBarcroftMedaltoProfessorwholeddevelopmentofOxfordvaccine.html\",\"favicon\":\"\"},{\"id\":\"60\",\"title\":\"Sarah Gilbert receives Royal Society of Chemistry Honorary ...\",\"description\":\"Apr 23, 2025 · The Honorary Fellowship was awarded to Professor Gilbert for her outstanding work in co-developing the Oxford/AstraZeneca COVID-19 vaccine.Missing:  titles | Show results with:titles\",\"url\":\"https://www.psi.ox.ac.uk/news-and-opinion/sarah-gilbert-receives-royal-society-of-chemistry-honorary-fellowship\",\"favicon\":\"\"},{\"id\":\"61\",\"title\":\"Woxsen University's post - Hyderabad - Facebook\",\"description\":\"Aug 31, 2025 · We are honoured to confer the Woxsen Luminary Award for Outstanding Research Contributions, 2025 upon Dr. Dame Sarah Gilbert, Professor of ...\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://www.facebook.com/woxsen/posts/we-are-honoured-to-confer-the-woxsen-luminary-award-for-outstanding-research-con/796123656403959/\",\"favicon\":\"\"},{\"id\":\"62\",\"title\":\"Professor Dame Sarah Gilbert delivers 44th Dimbleby Lecture\",\"description\":\"Dec 7, 2021 · As a vaccinologist, I was planning to continue my work on developing vaccines against influenza, Lassa fever, Nipah and various other unpleasant ...Missing:  biography | Show results with:biography\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://www.ox.ac.uk/news/2021-12-07-professor-dame-sarah-gilbert-delivers-44th-dimbleby-lecture\",\"favicon\":\"\"},{\"id\":\"63\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.bbc.co.uk/iplayer/episode/m0012b15/the-richard-dimbleby-lecture-dame-sarah-gilbert\",\"favicon\":\"\"},{\"id\":\"64\",\"title\":\"Professor Dame Sarah Gilbert delivers second 500th Anniversary ...\",\"description\":\"Jul 1, 2025 · Professor Dame Sarah Gilbert delivers second 500th Anniversary Lecture ... The event was chaired by Christ Church alumnus and BBC News Health ...Missing:  engagements | Show results with:engagements\",\"url\":\"https://www.chch.ox.ac.uk/news/professor-dame-sarah-gilbert-delivers-second-500th-anniversary-lecture\",\"favicon\":\"\"},{\"id\":\"65\",\"title\":\"UCL Prize Lecture: “It's a very exciting time to be a vaccinologist”\",\"description\":\"Nov 14, 2024 · Leading UK scientist Professor Dame Sarah Gilbert, whose research team designed and developed one of the principal Covid-19 vaccines, helping save millions of ...\",\"url\":\"https://www.ucl.ac.uk/news/2024/nov/ucl-prize-lecture-its-very-exciting-time-be-vaccinologist\",\"favicon\":\"\"},{\"id\":\"66\",\"title\":\"Vaccine Centre Annual Lecture: Professor Dame Sarah Gilbert\",\"description\":\"The lecture will be delivered by Professor Dame Sarah Gilbert and will be followed by a Q\u0026A session. Speaker ... Athena Swan Bronze Award · Accessibility ...\",\"url\":\"https://www.lshtm.ac.uk/newsevents/events/vaccine-centre-annual-lecture-professor-dame-sarah-gilbert\",\"favicon\":\"\"},{\"id\":\"67\",\"title\":\"Doherty Institute Media Conference_COVID-19 Vaccines ... - YouTube\",\"description\":\"Sep 26, 2023 · Doherty Institute Media Conference_COVID-19 Vaccines with special guest Professor Dame Sarah Gilbert. 323 views · 2 years ago ...more. Doherty ...Missing:  engagements | Show results with:engagements\",\"url\":\"https://www.youtube.com/watch?v=7lJo0MqamFE\",\"favicon\":\"\"},{\"id\":\"68\",\"title\":\"How two professors behind Oxford's vaccine stand to make MILLIONS\",\"description\":\"Dec 30, 2020 · Professor Gilbert is married to fellow scientist Rob Blundell and they have two daughters, Susannah and Caitlin, who went to Oxford, and son ...\",\"url\":\"https://www.dailymail.co.uk/news/article-9098411/Troubled-path-approval-Oxfords-vaccine-professors-jab-make-MILLIONS.html\",\"favicon\":\"\"},{\"id\":\"69\",\"title\":\"Vaccinologist Sarah Gilbert: 'We need to be better prepared for a ...\",\"description\":\"Jun 26, 2022 · The woman who co-developed the AstraZeneca vaccine on reassuring doubters, her new book and having a baby penguin named after her.\",\"url\":\"https://www.theguardian.com/society/2022/jun/26/vaccinologist-sarah-gilbert-vaxxers-astrazeneca-we-need-to-be-better-prepared-for-a-new-pandemic\",\"favicon\":\"\"},{\"id\":\"70\",\"title\":\"Sarah Gilbert's Triplets Participated in AstraZeneca Vaccine Trial\",\"description\":\"Nov 23, 2020 · All three of her children now study biochemistry. Gilbert's daughters, Caitlin and Susannah, attend Oxford, while her son, Freddie, goes to the ...Missing:  husband life\",\"url\":\"https://www.businessinsider.com/sarah-gilbert-children-astrazeneca-oxford-coronavirus-vaccine-trial-2020-11\",\"favicon\":\"\"},{\"id\":\"71\",\"title\":\"Hackers, anti-vaxxers and giving her triplets the jab - The Telegraph\",\"description\":\"Jul 24, 2020 · Professor Sarah Gilbert's Oxford team is leading the global race. Here she explains why its a family affair.\",\"url\":\"https://www.telegraph.co.uk/women/life/hackers-anti-vaxxers-giving-triplets-jab-meet-woman-behind-britains/\",\"favicon\":\"\"}],\"images\":[{\"id\":\"33254e6926ea\",\"caption\":\"Sarah Gilbert\",\"url\":\"./_assets_/Dr.Sarah_Gilbert.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"33254e6926ea\",\"caption\":\"Dr. Sarah Gilbert\",\"url\":\"./_assets_/Dr.Sarah_Gilbert.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0}],\"fixedIssues\":[],\"slug\":\"Sarah_Gilbert\",\"title\":\"Sarah Gilbert\",\"content\":\"$1f\",\"description\":\"Sarah Gilbert\\n\\nSarah Gilbert\\nDame Sarah Catherine Gilbert DBE FRS FMedSci (born April 1962) is a British vaccinologist serving as the Saïd Professor of Vaccinology at the University of Oxford's...\",\"metadata\":{\"categories\":[],\"lastModified\":\"1761583466\",\"contentLength\":\"31098\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"30432\",\"recentViews\":\"30432\",\"dailyAvgViews\":1014.4000244140625,\"qualityScore\":1,\"lastViewed\":\"1761882062\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761882062463,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Sarah_Gilbert\"],\"queryHash\":\"[\\\"page\\\",\\\"Sarah_Gilbert\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Sarah Gilbert\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Dame Sarah Catherine Gilbert DBE FRS FMedSci (born April 1962) is a British vaccinologist serving as the Saïd Professor of Vaccinology at the University of Oxford's Jenner Institute. Her research centers on viral vectored vaccines designed to elicit robust T cell and B cell immune responses against infectious diseases, including influenza and emerging pathogens such as MERS coronavirus, Nipah virus, and Lassa virus. In January 2020, Gilbert became the Oxford Project Leader for ChAdOx1 nCoV-19,...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"5\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"6\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Sarah_Gilbert\"}],[\"$\",\"meta\",\"7\",{\"property\":\"og:title\",\"content\":\"Sarah Gilbert\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:description\",\"content\":\"Dame Sarah Catherine Gilbert DBE FRS FMedSci (born April 1962) is a British vaccinologist serving as the Saïd Professor of Vaccinology at the University of Oxford's Jenner Institute. Her research centers on viral vectored vaccines designed to elicit robust T cell and B cell immune responses against infectious diseases, including influenza and emerging pathogens such as MERS coronavirus, Nipah virus, and Lassa virus. In January 2020, Gilbert became the Oxford Project Leader for ChAdOx1 nCoV-19,...\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Sarah_Gilbert\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:alt\",\"content\":\"Sarah Gilbert\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"17\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:43.466Z\"}],[\"$\",\"meta\",\"18\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:title\",\"content\":\"Sarah Gilbert\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:description\",\"content\":\"Dame Sarah Catherine Gilbert DBE FRS FMedSci (born April 1962) is a British vaccinologist serving as the Saïd Professor of Vaccinology at the University of Oxford's Jenner Institute. Her research centers on viral vectored vaccines designed to elicit robust T cell and B cell immune responses against infectious diseases, including influenza and emerging pathogens such as MERS coronavirus, Nipah virus, and Lassa virus. In January 2020, Gilbert became the Oxford Project Leader for ChAdOx1 nCoV-19,...\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"23\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"24\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="ZTM1MTJiMjEtNTViMi00NDExLThmNDYtM2QwYjQ5YzA5MWNi">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Sarah_Gilbert\"}]}]\n"])</script></body></html>